Maria Eugenia Novara

Dr. Maria Eugenia Novara

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
LPLavinia Piazza
Lavinia Piazza
ACAnna Carollo
Anna Carollo
EMEnrica Di Martino
Enrica Di Martino
MNMaria Eugenia Novara
Maria Eugenia Novara
SCSofia Cutaia
Sofia Cutaia
SRSergio Rizzo
Sergio Rizzo

18 September 2019 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
FGFilipa Grilo
Filipa Grilo
MNMaria Eugenia Novara
Maria Eugenia Novara
MDMaria Cristina D'Oca
Maria Cristina D'Oca
SRSimona Rubino
Simona Rubino
Riccardo Lo BiancoRiccardo Lo Bianco
Riccardo Lo Bianco
VSVita Di Stefano
Vita Di Stefano
Studying the sensory profile and chemical composition of monovarietal extra-virgin olive oils (EVOOs) is important to define and manage their quality and uniqueness. Chemical and sensory traits of olive oils from 14 minor Sicilian olive genotypes in comparison with oils from six major Sicilian and three international cultivars were analysed. Oils were extracted in 2015 from fruit of the 23 genotypes grown in an experimental orchard at a planting density of 1140 trees ha−1. Fatty acid composition, phenol composition, carotenoid content and antioxidant power were determined and analysed using univariate and multivariate procedures, in particular Nocellara Etnea along with carotenoid, phenol content and good sensory attributes, producing the best quality EVOO among the genotypes in trial. These results show that some Sicilian accessions used in this study may represent valid alternatives to produce high-quality EVOOs in modern, hedgerow planting systems.

11 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CSCatherine Smith
Catherine Smith
MNMaria Eugenia Novara
Maria Eugenia Novara
ACandrea cona
andrea cona
ADAnna Dolcimascolo
Anna Dolcimascolo
GCGiulia Cancellieri
Giulia Cancellieri
APAlessio Provenzani
Alessio Provenzani
The SARS-CoV-2 infection has been associated with important mortality, particularly in immunocompromised patients, including solid organ transplant (SOT) recipients. Remdesivir (RDV) is an antiviral drug that has proven to be effective in reducing the replication of the virus in host cells, by which it may reduce the progression of symptoms and, consequently, the length of hospital stay and mortality. Randomized controlled trials have evaluated its use in the general population but never in SOT recipients. For the first time in this review, the safety and efficacy of RDV is evaluated in this specific population. The literature research was conducted using PubMed/MEDLINE and Scopus databases from 1 January 2020 to 24 November 2023, and 23 studies were analyzed. Although no clinical studies specifically evaluating this population have been conducted yet, RDV is likely safe for SOT patients when compared to the general population, so prescribers should consider utilizing RDV in SOT patients who are at high risk for progression to severe COVID-19. Future research will allow for the confirmation of the observed results and the acquisition of broader and clearer data regarding the safety and efficacy of the drug in this specific setting.

5 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MNMaria Eugenia Novara
Maria Eugenia Novara
MCMartina Chirulli
Martina Chirulli
PVPatrizio Vitulo
Patrizio Vitulo
ACAnna Carollo
Anna Carollo
APAlessio Provenzani
Alessio Provenzani
Background: Idiopathic pulmonary fibrosis (IPF) is an incurable disease with limited therapeutic options and a poor prognosis. Current standard therapies are characterized by drugs or surgical strategies with limited effects, as they are either not curative or their use is restricted to a specific subset of the population. The aim of this scoping review is to evaluate the drugs currently under investigation in Phase II and Phase III trials and provide an overview of the mechanisms of new therapeutic strategies for IPF. Methods: The search strategy was conducted in accordance with PRISMA guidelines and included studies conducted on adults with IPF retrieved from the registered ClinicalTrials.gov database up to 31 December 2025. Results: Nineteen studies were included. The clinical trials investigate key signaling pathways and molecular targets, including MAPK, RhoA/ROCK, PDE4B/cAMP, Wnt/β-catenin, Hedgehog/SMO, IL-11/STAT3, and LPA/autotaxin, as well as extracellular receptors and mediators such as CSF1R, TBXA2R, and WISP1. Conclusions: Ongoing clinical research in IPF reflects a broad diversification of molecular targets; however, translational success remains limited. Current evidence suggests that biological complexity, pathway redundancy, and systemic constraints significantly restrict the clinical impact of single-target strategies. Future progress will likely depend on improved patient stratification, combination approaches, and biomarker-guided trial design rather than isolated pathway modulation.

1 January 2019
Verified
Conference Paper
Closed access
JIJuan Francisco P. Iñigo
Juan Francisco P. Iñigo
RVRenzo Vargas
Renzo Vargas
MNMaria Eugenia Novara
Maria Eugenia Novara
MPMartin Pereira
Martin Pereira
ICIgnacio Cambon
Ignacio Cambon
ESErnesto Schwarz
Ernesto Schwarz

26 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MNMaria Eugenia Novara
Maria Eugenia Novara
MCMartina Chirulli
Martina Chirulli
PVPatrizio Vitulo
Patrizio Vitulo
ACAnna Carollo
Anna Carollo
APAlessio Provenzani
Alessio Provenzani
There was an error in the original publication